






Hepatitis C is a blood-borne virus which predominantly affects the cells of the liver and is 
spread by direct exposure to infected blood, for example by sharing needles. It has be-
come known as a ‘silent killer’; an individual can have it for years without any symptoms, 
or its symptoms, such as depression, fatigue, skin problems, pain and digestive problems, 
can be attributed to other causes.  
Despite the prevalence of hepatitis C, relatively little is known about it among the general 
public. Its impacts, however, can be far-reaching. Not only can it be fatal, sometimes 
causing fibrosis and cirrhosis of the liver, liver cancer or end stage liver disease, but it can 
also have other detrimental impacts on the individual who has contracted it, and those 
around them. 
Adfam has been funded by Gilead Sciences to research the impact of hepatitis C on the 
family members of people who inject drugs (PWID). Their experiences are largely un-
known, and this research begins to fill that gap.  
Hepatitis C in the UK 
A recent report from Public Health England (PHE) stated that an estimated 214,000 peo-
ple are living with chronic hepatitis C in the UK. Intravenous drug use is the most im-
portant risk factor for infection. Around half of PWID are thought to be infected in England 
and Wales, with levels being lower in Northern Ireland (23%) but higher in Scotland 
(57%).
1 
While those who inject drugs are most at risk of contracting hepatitis C, it can also 
be transmitted by sharing other drug paraphernalia such as crack pipes or straws. 
Hepatitis C was the most common infection among PWID in 2015, with two in every five 
people who inject psychoactive drugs living with chronic hepatitis C. Of those who inject 
image and performance-enhancing drugs, around one in twenty have hepatitis C.
2
 Cur-
rent levels of transmission among young or new injectors suggest that hepatitis C virus 
(HCV) infection is often acquired relatively early in an individual’s injecting career,
3
 mean-
ing that even those who have not injected drugs over a sustained period of time are still at 
risk of infection. Numbers of new HCV infections have remained relatively stable over re-
cent years.
4 
However, despite intravenous drug users being one of the groups most at 
risk of contracting hepatitis C, only around one half of PWID sampled in UK surveys were 
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aware of whether or not they have been infected. This figure has remained relatively sta-
ble over the last five years.
5
 
Recent research has suggested that there are a variety of reasons which have led to a 
delay in diagnosis: “limited HCV relevance, felt wellness, stigma, compartmentalization of 
former injecting practices, unexplained symptoms and general practitioner inaction.”
6 
A 
2017 report by The Hepatitis C Trust has suggested that raising public awareness of hep-
atitis C will be vital in increasing the number of people who get tested, and thus diag-
nosed.
7
 The early diagnosis of HCV infection is important so that people can access the 
most effective treatment and care.
8
 PHE has recommended wider rolling out of testing to 
more individuals at risk of infection, including to PWID.
9
 It has also recommended intro-
ducing initiatives to further raise awareness of hepatitis C among professionals in primary 
care and other settings.
10
 
In May 2016, the UK Government pledged its support for the World Health Organisation’s 
goal of eliminating hepatitis C as a major public health threat by 2030.
11
 The WHO Global 
Health Sector Strategy sets out targets to work towards this goal.
12
 These include reduc-
ing new cases of chronic HCV by 30% by 2020 and 80% by 2030, and diagnosing 30% of 
people with HCV by 2020 and 90% by 2030. In order to meet these targets, Public Health 
England believes there needs to be a radical change in the response to hepatitis C 
among PWID.
13
 Raising awareness of hepatitis C will be a major part of this, and PHE 
has called for more to be done to increase diagnoses, ensure easier access to testing 
and treatment and further develop care pathways and support for people with HCV.
14
 
There is agreement that the ambitious goal of eliminating hepatitis C as a public health 
threat by 2030 is not unachievable; the treatment landscape has dramatically changed 
over the last few years. Previously, standard treatment of hepatitis C was limited to inter-
feron-based treatments. These had low success rates and often severe side effects. 
However, the introduction of direct-acting antivirals (DAAs) to treat hepatitis C has prom-
ised hope; they have cure rates of up to 90%, are shorter treatments and have far fewer 
side effects. The Hepatitis C Trust’s patient helpline reports that patients with experience 
of both old and new treatments are significantly more positive about the newer drugs, with 
many of them able to continue their lives as normal while undergoing treatment.
15
 Cur-
rently, however, NHS England has decided to limit DAA access in the UK to 10,000 peo-
ple per year, despite the National Institute of Health and Care Excellence recommending 
them as ‘cost-effective’ in 2015. The Hepatitis C Trust unsuccessfully made a legal chal-
lenge against this decision, arguing that the new treatments should be available to all. 
5 Ibid. 
6 Harris, M.; Ward, E.; Gore, C. (2016) Finding the undiagnosed: a qualitative exploration of hepatitis C di-
agnosis delay in the United Kingdom. Journal of Viral Hepatitis 23. p.479 
7 The Hepatitis C Trust (2017) Patient Perspectives Report 2017, London. p.9 
8 Public Health England (2016) Hepatitis C in the UK 2016 Report, London. p.13 
9 Ibid. p.14 
10 Public Health England (2017) Hepatitis C in England 2017 Report, London. p.10 
11 The Hepatitis C Trust (2017) Patient Perspectives Report 2017, London. p.7 
12 Public Health England (2016) Hepatitis C in the UK 2016 Report, London. p.25 (Appendix 1) 
13 Ibid. pp.8,21 
14 Ibid. p.6 
15 The Hepatitis C Trust (2017) Patient Perspectives Report 2017, London. p.16 
 
 
PHE stated in its recent report that as the new treatments are rolled out, a rapid reduction 
in severe morbidity and mortality is expected.
16
 
In 2016, Gilead Sciences launched the I’m Worth… campaign, a disease awareness pro-
gramme aimed at addressing the stigma that many people with hepatitis C face, and en-
couraging and empowering those living with hepatitis C to access care and services no 
matter how or when they were infected.
17
 
Experiences of living with hepatitis C 
Research has shown that living with hepatitis C can have a severely detrimental impact 
on the individual, and this impact is not just confined to the physical symptoms and risks 
posed by subsequent health conditions.  
Reaction to diagnosis 
The reaction to the diagnosis among patients can vary. One study in Australia found that 
“participants were almost evenly divided between those who described the diagnosis as 
distressing and those who reported being unconcerned.” It found that most of the people 
who were not concerned about the hepatitis C diagnosis also reported regularly injecting 
drugs at the time of diagnosis.
18
  
A recent report from The Hepatitis C Trust found that the distressing nature of the diagno-
sis was compounded by a lack of provided information, leading patients to conduct their 
own research online, and receiving the news that they had tested positive in an unsuita-
ble manner, for example over the phone or by a receptionist.
19
 This report found a lack of 
awareness of hepatitis C among patients, members of the public and health professionals 




Despite the increased hope following the introduction of DAAs, their rationing has been 
found to have a negative impact on patients following diagnosis. Another report from The 
Hepatitis C Trust, this time researching the perspective of nurses, found that nurses are 
concerned about their patients’ mental health as a result of delays to treatment, with the 
inability to access treatment reinforcing low self-esteem among patients and leaving them 
feeling “very upset” and “in limbo”.
21
 The rationing of DAAs has led to clinicians being ad-
vised to “manage patient expectations” about the benefits of a HCV cure, but recent re-
search has suggested that these benefits are not merely physical, and so should be taken 
into account as well.
22
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A common theme in research into experiences of living with hepatitis C is stigma, which 
can have a variety of negative effects on people. Very often, this stigma is an extension 
of the stigma surrounding substance use, due to the association of HCV infection with in-
jecting drug use.
23
 Stigma has been found to have a detrimental impact on quality of life, 
with fear around disclosing and transmitting HCV infection, and difficulties in employment 
and sexual relationships.
24




A 2016 qualitative study into diagnosis delay in the UK found that stigma was a key fac-
tor; one participant reported not being asked about drug use by their GP – and put that 
down to the stigma which surrounded the issue: “No GP has ever said ‘Have you used 
drugs?’ because there was a huge stigma and there still is a huge stigma.” Another de-
scribed not wanting to know because of “The shame of it… I think what I’d put my family 
through… maybe I didn’t want to go back to it being so long ago, it [my drug use] was 30 
years ago.”
26
 Stigma was often felt to be perpetuated due to an absence of HCV re-




A 2009 New Zealand study into HCV stigma found that one participant had internalised 
societal stigmas about injecting drug use to such an extent that he viewed his hepatitis C 
diagnosis as a moral designation which put him off from telling friends,
28
 and another re-
garded herself as dirty due to comments from her mother: “She goes, ‘Don’t tell any of my 
friends, because it’s dirty. I mean everyone knows that you get that from using nee-
dles.’”
29
 Often the stigma was exacerbated by misconceptions about infectivity; one wom-
an recounted being told by a nurse in a hospital that she was not allowed to use the bath 
due to having hepatitis C.
30
 Other research has suggested that the health care setting is 
the most common site of experienced HCV discrimination by PWID, potentially because 
this is where people are most likely to disclose their HCV status.
31
 
Likewise, a 2012 qualitative study into barriers to hepatitis C treatment for PWID found 
that stigma played a part, with one man saying “Hep C, it’s much more of a stigma about 
injecting and being an injecting drug user and therefore, it’s dirty, you know, you’ve got it 
yourself, you’ve gone out and got it.”
32
 Several participants were reluctant to tell others 
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about their hepatitis C diagnosis: “it’s just scary to some people”. This stigma was often a 
primary motivator to enter into HCV treatment.
33
 
This study recommended increasing HCV awareness and knowledge among the partners 
and families of affected individuals so that stigma could be reduced and care could be im-
proved.
34
 Similarly, a recent report by The Hepatitis C Trust has recommended that the 
Government implement a public awareness campaign, aimed at tackling stigma and en-
couraging people to access testing.
35
 
Relationships with other family members 
Another key impact of having hepatitis C – which is particularly pertinent to our research – 
is the effect it has on patients’ relationships with family members and friends. 
A qualitative longitudinal study conducted between 2012 and 2015 found a number of so-
cial impacts on people living with hepatitis C. Relationships with family members often 
suffer due to fears about transmission. One man spoke of wanting to be “back to normal” 
because the mother of his son tells him “Oh no, you don’t see your son, because it’s in-
fectio[us]”
36
, another was told “We all sit at this side of the table and you can sit on the 
settee over there. Don’t play with the kids too rough.”
37
 and another spoke of being reluc-
tant to play with his grandchildren: “I like to play with them and have a rough and tumble. I 
haven’t been so close to them since I’ve had it… it’s sad, especially when they jump and 
try and give me a cuddle.”
38
  
Another participant spoke of ceasing all sexual relationships, despite HCV rarely being 
transmitted heterosexually: “I found out I got hep C… that’s it, my life’s over, that means 
women are gone… I’m scared of giving it to them and I think to myself, if I can get rid of it 
I don’t have to worry… It was the biggest [treatment incentive] for me.”
39
 Another partici-
pant stated that even if his wife had been better informed about the infectivity of HCV, she 
would still have been concerned about it.
40
 The study found that the physical effects of 
HCV also had a social impact, with participants citing the effect that a lack of energy can 
have.
41
 Following successful treatments, participants found that they were able to socially 
reconnect to those around them.
42  
A 2009 New Zealand study into HCV stigma found other impacts on interactions with fam-
ily members and friends. For example, some relatives and friends brought their own cups 
when visiting them or refused bodily contact, while others felt silenced by their friends, 
family and acquaintances who did not want to hear about their illness: “social stuff I found 
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the hardest… people don’t actually want to know about chronic illness.”
43
 
A 2012 study documents the impact on family members and friends in a different way; 
particularly during HCV treatment, participants relied on family members for doing every-
day tasks as well as emotional support. One participant felt like she was a burden on her 
family: “I’ve got family support… it makes it even worse really because it makes it harder. 
You feel like it’s all like you ain’t just bringing yourself down, you’re bringing that ship 
down with you. It’s like you’re hurting other people as well. I prefer to be on my own.”
44
 
The study also found that caring responsibilities were a challenge for participants under-
going treatment, as they themselves also needed support.
45
 The study recommended 




Families affected by a loved one’s drug use 
It is estimated that in the UK there are at least 1.5 million adults who are significantly af-
fected by a family member’s drug use.
47
 While it is unclear how many of these have family 
members who inject drugs, an estimated 122,894 people in the UK inject drugs,
48
 mean-
ing that a significant number of family members are affected. Given the prevalence of 
hepatitis C among PWID (around half in England and Wales),
49
 it is likely that this is an 
issue which affects a large number of family members. 
The experiences of family members are largely undocumented; this research begins to 
rectify this by shining a light on what it is like to be a family member of someone who in-
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Adfam ran two online surveys from December 2016 to February 2017 using a conven-
ience sample. Twenty seven people participated. One survey was for family members of 
people who have been diagnosed with hepatitis C due to injecting drugs and was an-
swered by 17 people. The other was for family members of people who inject drugs, and 
are therefore at risk of contracting hepatitis C, but do not have a diagnosis, and was an-
swered by 10 people. 
Six phone interviews with family members were conducted between March and April 2017 
to go into more depth. Participants were recruited via promotion online, on social media 
and using Adfam’s existing networks. All names have been changed and models have 
been used for photographs. 
The family members 
A variety of family members were involved in the research. The family members in the at 
risk survey were affected by the drug use of their child (5), sibling (3), parent (1) and sis-
ter-in-law (1). The family members in the diagnosis survey were affected by the hepatitis 
C diagnosis of their parent (3), child (3), sibling (5), partner (5) and cousin (1). The family 
members in the phone interviews were mothers (4) and partners (2).  
Knowledge 
Awareness of hepatitis C 
among family members of 
people who inject drugs is 
fairly high; each participant 
was at least somewhat fa-
miliar with it. One partici-
pant told us that they were 
a trained substance misuse 
practitioner and so was 
very knowledgeable on the 
subject. However, several 
family members felt that 




“[My knowledge of hepatitis C] is not in depth, it’s probably more like the aver-
age person. I don’t have an in depth medical knowledge. I am very much aware 
of it: I know that it affects the liver, I know that not everybody dies with it, and I 
know medication has changed a lot over the years.” 
“I guess I have a basic understanding unless it has changed in the last few 
years.” 
Family members had heard about hepatitis C in a variety of places, the most common be-
ing from a drug and alcohol service. Others, such as Sue, had heard about it through their 
own work and experiences: 
“I’ve basically heard about it because my sister-in-law died of it 18 years ago. 
About 25 years ago I was working for a women’s refuge and we’d done a lot of 
stuff – a lot of the women coming into the refuge who had suffered domestic vio-
lence had had partners involved in drink and drugs. We had a lot of in-house 
training around AIDS and drug use and I heard about hepatitis C then.”  
Carol felt that, while she had heard a bit about hepatitis C, this was not enough to stop her 
worrying. 
“I knew a bit about hepatitis C through [a family support group] but not enough 
for me to stop worrying, you know about what I mean? We had [the family sup-






Concern about hepatitis C was 
commonplace among the family 
members who participated in our 
research, with most saying that 
they were very worried. A variety 
of reasons for this worry were giv-
en: one person was worried about 
the potential impact on their broth-
er’s partner and child as he is still 
injecting, while another was wor-
ried about their child being re-
infected with it despite already 
having been diagnosed. 
“I am massively worried. Interestingly he has just recently come out of hospital, 
and we had a conversation around this. He was tested for everything when he 
was in there and told to wait three months before being tested again. His last 
tests were clear. He went into hospital because he was injecting in his groin re-
sulting in a very nasty deep infection, a DVT and his leg swelled up to twice its 
normal size. He knows he should get tested because he is sharing needles. I 
am massively scared that this [sharing needles and contracting hepatitis C] is 
something that is possible.” 
Carol was worried about her son contracting hepatitis C, but found it hard to talk to him 
about the issue:  
“Yes, I was worried about him getting it… I used to check that [my son was] not 
sharing needles. But he denied being on drugs!” 
However, not all family members were worried about the risk of their family member con-
tracting hepatitis C. For Sue, the worry of hepatitis C is not as great as some of the other 
problems she is facing with her son.  
“I’m not worried about it because the aggression from my son far outweighs the 
hepatitis C. He knows the risks and I know the risk. If those are risks which he is 
prepared to take, then that’s for him to decide. For me, it is more about manag-
ing his drug use and putting in boundaries when he is abusing the steroids; 






Many family members turned 
this worry into encouraging 
their loved one to get tested 
for hepatitis C, often as part of 
a wider message of harm re-
duction. 
“Currently, he has had 
negative hepatitis C 
tests. He was told to wait 
another three months for 
the next test – not that he 
is tested every three 
months – but he has shared with me that he has been tested over the years. I 
raised it with him as something he needs to do if he is sharing needles.”  
“Yes, we’ve had discussions about it. I’ve told him how unhappy I am about the 
needle use. I’ve told him about being clean. We’ve discussed the need for hy-
giene… I like to think that he is good about it. But that doesn’t mean that he is.”   
Likewise, Carol encouraged her son to get tested, but acknowledged that she only knows 
what he tells her: 
“I often asked him to get tested and he said he was being tested. I can’t do any-
thing more if he says yes.” 
However, Diana did not encourage her daughter to be tested, linking this to the often se-
cretive and hidden nature of drug use. 
“I didn’t encourage her to be tested – I didn’t think it would happen. Her using 
was hidden from us for quite a long time… Maybe the addicts need to get more 
information as well, because I don’t think she was aware at all about it. She nev-
er gave any indication that she knew about it but then addicts hide everything.” 
Most of the injecting drug users had been tested for hepatitis C, although two family 
members were not sure whether their loved one had been tested.   
Barriers to being tested  
Despite the high proportion of testing for hepatitis C, a number of barriers to being tested 
were identified. The most common of these were connected to stigma. Amanda described 




“When he went into hospital, he was dealt with a lot of contempt by a lot of peo-
ple. He came out homeless – on crutches, with a massive groin injury which 
needs attending – with nothing in place. I phoned the nurse who discharged 
him, asking what was the care plan for him, but she said that they have done 
their bit and he has to get on with it. I have sadly encountered some people – 
although there have been some wonderful people in his recent experiences – 
but I have encountered some very disrespectful, unprofessional attitudes. He 
has been spat at, just because he uses drugs. He told me this was just a win-
dow into his world. There is condemnation of people who use drugs.” 
A third of participants cited their loved one not wanting to know the outcome of the test as 
a factor, with one person describing their loved one’s “fear related to health anxiety”. This 
was also the case for Amanda’s son: 
“He’s probably really scared of finding out [if he has hepatitis C] and the dan-
gers of sharing if he found out.” 
Interestingly, one survey participant linked the rationing of direct-acting antivirals (DAAs) 
to a reluctance to find out the results: 
“Lack of tolerable treatments for those without late-stage liver disease… I’d ra-
ther not know. I’d rather not test until the better treatments are available to all.” 
Amanda went on to point out that, for her son, being tested for hepatitis C was not some-
thing he was particularly concerned about. 
“The other obvious point is that when someone is in the throes of that lifestyle, 
they don’t think rationally as you or I, they don’t see it [testing for hepatitis C] as 




Impact on family life 
The impact hepatitis C had on day-to-day family life varied among the family members. 
One said that “everything changed” while others said that it barely had an impact. 
Seven family members out of the 17 who answered the survey (41%) believed that the 
hepatitis C diagnosis had pushed the family further apart, whereas only one thought that 
it had brought the family closer together.  
As hepatitis C can be asymptomatic and thus undiagnosed for years, it can cause remind-
ers of previous drug use which people had thought they had put behind them: 
“Past drug use from over 25 years ago is impacting now and that is difficult to 
accept and deal with for him (and me).” 
 
 
Coping with symptoms of hepatitis C and side effects of medication 
For several family members, dealing with the symptoms of hepatitis C and the side effects 
of medication had a negative impact on family life, with one family member citing 
“irritability, tiredness and low mood”. Due to the hepatitis C diagnosis, one family member 
had to become a carer for her mother, whilst trying to keep up her fulltime job.  
Others mentioned that they now had to support their loved one:  
“[I] needed to be with my son when he was ill.” 
For those who have lost a loved one to hepatitis C, the impact is only too stark: 
“The effects are profound for living with any sort of illness and the effects of him 
not being here anymore.” 
Fears about transmission of hepatitis C 
The infectious nature of hepatitis C, often coupled with a lack of knowledge about how it 
is transmitted, is a source of worry for several family members, and thus has an impact on 
their actions and how they relate to their family member. One family member described 
their fear: “[My] son was very anxious and paranoid that he would catch it. This made me 
feel really upset and anxious too.” Another referred to people being made “separate from 
family as worried about infection”. Even information about the transmission of hepatitis C 
did not alleviate these fears: “[the] provision of information [was] unable to dispel myths 
around transmission of HCV [which led to] behaviour change within the family and es-
trangement of [my] mother from some of her grandchildren.” 
Fears of transmission impacted the way Carol acted when she was around her son. 
“I can’t be normal, I know it sounds awful, doesn’t it? When he goes upstairs, I 
follow him. I am a bit obsessive, making sure everything is cleaned out. That 
has an impact on you. He’ll come here and have a shower, and it takes me 
about an hour to clean it afterwards. I tell him that he is filthy and I am ashamed 
of him. I didn’t use to do that. He has been doing this for 30 years. He asked me 
to take him to the hospital, and I told him that I’m not going to, that he is filthy 
and that he is embarrassing. It’s not a normal life, is it?” 
She also described how she had to be tested for hepatitis C herself after she cut herself 
on her son’s razor when cleaning the shower, shortly before he told her that he had con-
tracted hepatitis C. 
“When he told me [that he had hepatitis C], I was devastated. I had cut myself 
on his razor when I was cleaning the shower a couple of weeks before he told 
me. I went straight to the doctors to get tested. I was really embarrassed. I know 
 
 
the receptionist from the local village and didn’t want her to know. I was tested 
for hep C and HIV and had to go and have another one because sometimes it 
lies dormant, and thankfully I was fine. It’s not very nice, is it? And the stigma, 
the stigma’s still there whether you like it or not.” 
These fears had an impact on the relationships within Diana’s family: 
“Everyone in my family was quite distraught because we didn’t know much 
about it and when we found out, we found out we might be able to pick it up as 
well. From me being the mum, I fell out with one of my children, my eldest son, 
because he was very angry and my daughter is the middle child and we had to 
look at things in a different light… My eldest son is so angry that he doesn’t talk 
about it and refuses to have a relationship with her which is a bit sad but it’s his 
choice. He refuses to communicate with her at all… He has a child and he 
doesn’t want his child involved in her life because of the drug use and because 
of the contagious disease.” 
Relationships within the family  
Relationships within the family were impacted by the hepatitis C diagnosis in other ways 
as well. 
Survey participants were split between those who thought it brought them closer to to-
gether and those who thought it pushed them further apart. One respondent said that it 
made no difference to relationships in their family. 
Several family members reported feelings of anger and worry, which had an impact on 




“[My son’s hepatitis C diagnosis] definitely [affected the relationship] with me 
and my partner, he is so angry he doesn’t say anything… He can’t forgive him-
self. My son didn’t tell us until it was too late. I’m stuck in the middle between 
them.” 
“I think it just left scars because it is a battle. It’s the same journey as any dis-
ease such as cancer because you watch them deteriorate. It made me incredi-
bly sad and annoyed and angry. You become intolerant of their illness and them 
even though they are doing their best to present themselves well. You get the 
worst side of it because you are one of the only people who knows.” 
One respondent experienced aggression and domestic abuse from her ex-husband which 
she put down to the treatment he underwent for hepatitis C. This was “the final thing that 
triggered me to divorce him”.  
Dealing with a family member’s hepatitis C diagnosis can also be a frustrating experi-
ence: 
“It’s pulled us together but my cousin who has it is using it as an excuse for not 
wanting to do anything with family or around home… He tells us he has symp-
toms then goes out with mates. None of us are challenging him but avoiding him 
now.”  
This participant went on to explain that their cousin says that he is too tired to do chores 
because he has hepatitis C, but then puts messages on Facebook saying that he is 
“milking it”. 
For John, his partner’s diagnosis with hepatitis C impacted the physical side of their rela-
tionship. 
“It did have quite an effect on the physical side, being aware of someone having 
a disease in their blood which can be quite easily transmitted. It did cause quite 
a bit of discomfort and a bit of distance between us for a while at the beginning.” 
Stigma 
There is often stigma surrounding hepatitis C due to its associations with injecting drug 
use, and this stigma can be experienced by the wider family as well.  
Carol was mortified after cutting herself on her son’s razor before she knew he had been 
diagnosed with hepatitis C. 
“It was all so embarrassing. It was very, very embarrassing at the doctors. I did-
n’t want the test results going through to the reception. There is doctor-patient 
confidentiality but the receptionist knows - that’s what’s embarrassing.” 
 
 
John remembered one specific incident of his partner accessing services: 
“I do remember one time years ago when she went to the dentist and when she 
went in she told him that she was hepatitis C positive and he refused to treat 
her. This was about 10 years ago. She was very upset about that and was quite 
embarrassed.” 
Diana said of her daughter: 
“The only person who received any stigma was my daughter. She has been in 
rehab four times. There was stigma at the drug and alcohol service definitely – 
she felt very uncomfortable telling them.” 
Katie described how her husband assumed that he would experience stigma: 
“He chose not to tell people because he was afraid of their reaction… He was 
afraid of being judged. He knew how he had contracted it, and he assumed eve-
ryone else knew about how he would have got it… The stigma was in his 
brain… His family have since said that they would not have cared if he had told 
them about the hep C. He was a quirky person, he would not have experienced 
any stigma if he had told people.” 
While several family members said that they had not experienced stigma from friends or 
family, they were still reluctant to tell other people, as Carol acknowledged: 
“My friends are brilliant, they do know how it has affected me. They come round 
for coffee mornings and they know they can come and it’s clean because they 
know me. I have good friends. I suppose I wouldn’t be telling people I don’t 
know well because I would worry what they are thinking of me.” 
Other family members worried about the stigma:  
“You worry about the stigma and can’t openly share the issue with your friends.”  
The secrecy could be isolating:  
“It’s kept as a secret, so I’m the only member of the family who knows.”  
Katie linked the shame and stigma with a lack of awareness about hepatitis C: 
“There’s no Elton John for hepatitis C! It’s alright to have HIV because it is glam-
orous and there is treatment and there is Elton John and people wearing red 
ribbons. There’s no-one out there for hepatitis C, it is all really stigmatised.”  
 
Katie’s story 
In September 2016, Katie’s husband, Richard, died of liver failure 
as a result of hepatitis C which he had contracted 25 years previ-
ously. He had injected drugs from the age of 18 until his early 20s. 
He was diagnosed 10 years ago, before Katie met him. 
“He told me about it pretty much straightaway when we met,” she 
says. “Originally it had no effect on me at all. It didn’t affect him 
massively apart from being in the back of his brain.” 
However, after Katie became pregnant with their daughter Amelia, 
Richard decided to undertake the interferon and ribavirin combina-
tion therapy.  
“He started it when our daughter was born. That treatment was horrific, I cannot tell you 
how horrific it is to live with that treatment… It’s just the most horrendous version of 
chemotherapy. He lost teeth, he lost weight, his sex drive etc. It lasted nearly the whole 
year. It is very hard. And after the end of it, [the hepatitis C] hadn’t gone. That was a real 
blow. [His hepatitis C diagnosis] didn’t bother us originally – it certainly didn’t bother me 
originally – but after the treatment it changed everything and changed who he was. And it 
rocked us. It was a vile treatment and it had a profound and lasting impact on our rela-
tionship. We argued like we never argued before. It made us stronger ultimately. It left 
lasting effects on us, physically, mentally and emotionally. ” 
The stress of Richard’s treatment took its toll on Katie: “It’s emotionally gruelling and 
tough. It changes you as a person supporting that person. You are on a parallel road, 
aiming for the same thing but the journey is different – his bumps were not my bumps. It’s 
just a different journey, because you are watching your loved one go through such a diffi-
cult time but it is so annoying... I was rubbish with it, I lost weight, I was bolshie and an-
gry. We suffered physically and emotionally in a different way.” 
In the intervening years, Richard “regained himself” but still had to cope with the symp-
toms of hepatitis C. In the autumn of 2015, he underwent DAA treatment which cleared 
the hepatitis C, but by this point his liver was already severely damaged. He chose not to 
tell Katie the full extent of the damage: “By the time he was admitted to hospital, he had-
n’t really noticed the full effect. He chose not to tell me the full extent of the damage. He 
was in so much pain in the last year. He used to hide it and sleep a lot… The latter years 
with him were fantastic because he chose not to tell me. He was frightened and didn’t 
want to scare me. I was very grateful because we could 
just live our lives.” 
Katie believes that there needs to be more awareness 
and openness around hepatitis C: “We need to encour-
age people to be open if a loved one has it… It’s a hor-
rible illness and people need to be aware of it. It is a 
really anonymous illness until it is too late. We need 
awareness and to be more mindful that it isn’t trivial – 
having hep C is not a trivial thing, being around some-
one with it is not a trivial thing. It leaves marks and 
scars on the people around them.” 
“Having hep C is not 
a trivial thing, being 
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Seeking information and support 
While awareness of hepatitis C among families of people who inject drugs was fairly high, 
many did not know about it in depth and so sought information from elsewhere, most 
commonly online. Two participants said that they work in the field of addiction and had 
heard about it through their work. 
Experiences of finding information varied. John and his partner had a positive experience: 
“At first we went to the [sexual health] clinic where we went to get tested. They 
had a lot of information there, quite a lot of leaflets and booklets… When she 
started some of the treatment for it, the nurses and the doctor gave quite a lot of 
information about the disease and the treatment and so on. I went with her one 
time and I asked questions. I got information from the professionals. We were 
quite well informed. All the information was quite easy to access.” 
While Diana had found information about hepatitis C, it was limited to the basics: 
“I’ve done research on the internet and spoken to my GP. It was very basic in-
formation though, for example don’t share toothbrushes and razors. I didn’t find 
too much detail about how the hepatitis gets into the bloodstream and I didn’t 
understand all the medical side of it.” 
Likewise, family members’ experiences of accessing support for their loved one and for 
themselves were mixed. The most common experience was a positive one, with one par-
ticipant describing the support as “very helpful”. Another participant had a generally posi-




“Great information given online and from professionals around condition and 
treatment options. Also that cousin is relatively well after scans – he then asked 
me to leave after this and came out saying they were wrong and he’s really bad. 
Staff came out to give leaflets.” 
However, there were also some negative experiences.  
“[There was a] variable response to my mother from staff. Attending Herpetolo-
gy was unproblematic but my mother felt stigmatised during some of her hospi-
tal appointments.” 
Another family member described the long wait to see a specialist, which meant that their 
loved one had yet to access support. 
Diana was at a loss as to where her daughter could get support: 
“[My daughter] doesn’t know, and I don’t know, any other places where she can 
get help. There’s help from the GP, I don’t know about drug and alcohol ser-
vices. She comes in and out of recovery a lot. There’s a blasé attitude about it 
everywhere. She went into rehab in January. I don’t think even they were both-
ered. In the rehab she went in, they didn’t seem to be interested.” 
On the other hand, both John and Katie acknowledged that there may have been more 
support out there, but their partners did not want to engage with it. 
“I think she probably was offered a counsellor but she didn’t engage with it or 
anything. She just sort of got support from the healthcare staff and from me and 
some of the family. She kept it quite private. She didn’t really tell a lot of people, 




“From my understanding, I used to moan that there was no support from the liv-
er unit. But they did try to get him in between appointments – he just didn’t go to 
them. He just went in and out for his treatment, and the nurses tried to get him 
in for other support but in between he didn’t engage with it.”  
Support for themselves 
None of the family members involved in the research had accessed support for them-
selves specifically around the issue of their loved one’s hepatitis C diagnosis.  
John felt that he had enough support from his family: 
“No, I didn’t [access support for myself]. I think I was offered counselling as well 
– it was quite a long time ago. I remember going to get the diagnosis and you 
do get help and are offered support but I was OK with my family and with my 
partner.” 
Diana found that attending a family support group helped her: 
“I go to Al-Anon and I find that very helpful. Because it starts off with alcohol an-
yway. It’s very difficult because you don’t want to talk about it. I can go to Al-
Anon and talk about it because everything you say is confidential. I have been 
going there on and off for about ten years.” 
However, this is in contrast to the lack of support she felt she had from her friends and 
others in her family: 
“I don’t mention it with friends. I do have a friend who is a psychiatric nurse and 
she understands a great deal and it is nice to talk to her. She listens and helps 
in what she says. But the rest of the family don’t know. I couldn’t tell my brother. 
He is a very professional person and he just wouldn’t understand it. He doesn’t 
understand her being a heroin addict anyway. It’s kind of like a secret, isn’t it?” 
Katie said that she did not look for support, but would have accepted it if she had been 
offered it: 
“I originally read up on it. There aren’t a huge number of hep C groups, they are 
pretty few and far between. There aren’t many groups nearby. My life is busy, 
I’m pretty bright and I self-manage myself. We were pretty good at figuring it out 
and just getting on with it. If someone had come to me and offered support, I 
would have said yes, but I didn’t look for it. It’s like living with someone with can-
cer treatment but covered in a cloud of shame and secrecy. There isn’t that lev-





The majority of family 
members in our research 
said that their loved one 
had accessed treatment 
after being diagnosed. 
They were asked what 
treatment their loved one 
received, and of those who 
specified treatment, there 
was a mixture of those who 
had had interferon-based 
treatments and those who 
had accessed the newer 
drugs. Two respondents said that their loved one is currently undergoing treatment, while 
another three said that their loved one was waiting for treatment. Diana described the de-
lays to her daughter receiving treatment: 
“It was only the other day that I spoke to the GP about hepatitis C (we both have 
the same GP). He referred her in October but she hasn’t heard anything. He 
said he would refer her again. There was no sort of follow up or anything like 
that.” 
Two family members said that their loved one had dropped out of the treatment process, 
one because they said they were too tired to go to the appointment, and another because 
their loved one had health complications. Another said that their loved one had been suc-
cessfully treated, but had later been re-infected. 
Involvement in treatment 
Several family members said that they had been involved in the treatment process, at-
tending appointments or being aware of what was going on. 
“I did go with her for a few hospital appointments. At the beginning of the treat-
ment and for the last one when she got the results back at the end, I went along 
with her.”  
“The GP is very helpful for her and for myself. He seems to have a lot of pa-
tience with her. He takes time and I’ve often been in the surgery with her.” 
“I was involved enough to know it was going on. We just carried on living. We 




While not being directly involved in her son’s treatment, Carol still encourages him to 
keep it up:  
“I still check on him to check he is having his treatment.” 
The effects of treatment 
Treatment for hepatitis C – particularly the older, interferon-based versions – can have a 
significant impact both on the individual and on those around them. 
John recalled the interferon treatment which his partner successfully underwent: 
“It was a six month period and it was tablets every day and once a week an in-
jection which she did herself. I remember it was tough but we had already been 
warned… It’s quite a difficult treatment and I know it has quite a few side ef-
fects… [She had] depression as well as the other side effects. Sleeplessness. 
She had hair loss and stomach aches and feeling flu-like. It used to be worse on 
the day when she had the injections, one day a week.” 
Watching his partner go through this was hard for John too: 
“At the time it was quite depressing really because there was nothing really I 
could do to help the symptoms. It was upsetting at the time.” 
Likewise, Katie’s husband’s experience of unsuccessful treatment was very negative: 
“It [interferon and ribavirin treatment] was horrific. I just think it is a barbaric 
treatment… It involved horrific weekly injections. It was endurance testing, psy-
chologically difficult. It physically ruins them at the time and afterwards.” 
 
 
Improving families’ experiences 
All of the family members who were involved in this research were asked how the experi-
ences of families of people who inject drugs and have contracted – or are at risk of con-
tracting – hepatitis C could be improved. Their recommendations can be split into five 
broad areas. 
1. Promote a greater awareness of hepatitis C among the general public to 
encourage testing and challenge stigma, through a national campaign 
and more information in healthcare settings. 
While all the family members involved in our research had some awareness of hepatitis 
C, many recommended that steps be taken to improve the awareness of the general pub-
lic. Several linked this to a reduction in stigma: 
“Nationwide campaigns to challenge stigma and to highlight that treatment is far 
more successful these days than was the case seven or eight years ago.” 
“There needs to be more awareness and less stigma, more people in the press 
being open about it.” 
Likewise, several family members thought that more coverage in the media would help: 
“Education could help, maybe more adverts on the TV about it.” 
“You don’t hear much about hepatitis C on television and radio – the media 
don’t get involved in it. There’s never anything about hepatitis C. You do get sto-
ries about heroin and drug use but no-one talks about hepatitis C. More infor-
mation and the public knowing more would be very helpful. Certainly in my case 
I knew nothing.” 
Others suggested having more information about hepatitis C in GP practices: 
“More info displayed in clinical areas. Leaflets, posters etc.” 
“Anything that is going to educate people, anything that is going to be put in 
doctors’ surgeries, information leaflets in places where people can see them, 
advertisements on websites; anything that can give people an education around 
it.” 
One participant noted that those who have not injected drugs for a long time are in dan-
ger of being uninformed due to not being in touch with services, as well as being reluctant 
to remember their previous lifestyle. Increasing the awareness of the general public may 
help reach this group of people and their families. 
 
 
2. Provide information about hepatitis C to family members of people who 
inject drugs. 
As well as greater awareness among the general public, many family members said that 
there should be information about hepatitis C provided specifically to family members of 
people who have contracted – or at risk of contracting – hepatitis C. Suggestions included 
leaflets or a family pack. 
“Families need to be educated in their own right so that they provide informed 
and appropriate support and responses to their loved ones and keep everyone 
concerned safe.” 
“I think family members would benefit from being informed, especially that hep 
C is no[w] completely treatable and that the treatment is no longer something to 
be feared.” 
Where children are involved, Diana stressed the vital role that grandparents play: 
“Grandparents are the answer – in my case my grandchildren were helped by 
myself… Grandparents are the ones who can help but they also need the infor-
mation.” 
Several family members linked an increase in information with a reduction in fears about 
transmission: 
“A relatives’ leaflet so I don’t under or over react e.g. washing cutlery.” 
“Offer of support to wider family to dispel myths.” 
3. Enable family members to be more involved in the treatment process. 
Several family members said that being more involved in the treatment process would 
benefit them, as not only would they be more informed, but they would also be in a better 
position to support their loved one. 
“Be part of care/support/recovery plan, be kept in the loop about treatment etc.” 
“Anything that is going to educate or involve family members with what is hap-
pening would be good.” 
One participant did acknowledge the need to gain the patient’s permission to do this:  
“The families/family members of those living with hepatitis C would first need to 
be identified and the permission of the person in treatment obtained to involve 
them in treatment/care planning before they can appropriately support their 
loved one.”  
 
 
Other participants emphasised the need to encourage people with hepatitis C to seek the 
support of their family: 
“Help for the person with hep C to consider the benefits of involving family 
members. This is not openly discussed in our family and I fear that this attitude 
just adds to the stigma and shame that those diagnosed feel.”  
Suggestions for involvement in treatment included offering to copy letters about appoint-
ments to family members so they can make sure their loved one attends and encouraging 
family members to attend appointments with their loved one. 
“It would be good for the whole family to go and see he is having treatment and 
bring it out in the open.” 
One participant related how they had not been involved: 
“We were not given information as we were not involved with his key-work ses-
sions and the drug service. We only found out due to a hospital admission.” 
4. Provide support for families in their own right. 
As well as providing support for their loved ones, family members felt that they needed 
support for themselves as well. Support groups and peer support were mentioned by a 
couple of people:   
“Support groups for family members would be really good. There are support 
groups for people with hep C but [I don’t know] of ones for family members. I 
have been to [a] hep C [group] with my daughter which was helpful.” 
“Peer support network, so that family members can speak to other family mem-
bers.”  
This would no doubt help to alleviate the loneliness and isolation experienced by many 
family members. 
“It is not easy, especially when one does not want the family to know: an extra 
burden.” 
“As a parent I don’t feel so alone knowing that there are other parents going 
through the same thing. It takes away that loneliness – it’s one hell of a lonely 
journey this.” 
This support should be accessible to all family members, regardless of whether or not 




“Family members of people at risk of contracting hepatitis C because they inject 
drugs should be offered support and information in their own right as I do not 
feel it is appropriate that they are left uninformed or unsupported if the drug us-
er does not want them involved in their treatment planning.” 
One participant referred to the financial implications of supporting a loved one with hepa-
titis C and said that there is currently little support for working families. 
5. Improve access to treatment for hepatitis C. 
Several family members referred to the limited access to the new treatments for hepatitis 
C and the negative impact that delays to treatment have on the wider family. 
“Treatment is available, but [it is] severely limited and seems to be based upon 
a post[code] lottery. It is extremely distressing [for] the individual and their fami-
ly not knowing when and if treatment will ever be available.” 
“Families have to support their loved one while they wait for treatment, this is 
very distressing for all concerned, particularly as the new class of drugs will 
clear the infection in most cases. No one can give any indication of how long 
the wait for treatment is.” 
“There needs to be more of this new treatment available – you shouldn’t have to 
be at death’s door.”  
One family member, who had contracted hepatitis C herself, praised the treatment itself, 
but said that the after-care was “almost non-existent”. 
Positives already happening 
However, some family members did recount positive experiences, and did not have spe-
cific recommendations. John’s partner was successfully treated for hepatitis C and they 
both found the hospital and staff very helpful: 
“From my experience, the hospital were very good. They gave us a lot of leaf-
lets and booklets. The staff were very helpful. If you are proactive and want to 
find out things and ask for help, help was available. I can’t think of anything else 
they could provide… the hospital and the NHS provided really high quality care 
and treatment. She was lucky because the treatment did work.” 
Another family member acknowledged that in many cases it is up to the individual to use 
the services: 
“It depends on the person, you only know what they tell you or let you attend. I 




It is clear from the family members involved in our research that hepatitis C does not just 
affect the person who has contracted it; it can have a large impact and wide-reaching 
consequences for the whole family. More needs to be done in terms of keeping families 
informed, involved and supported as they in turn support their loved ones along their hep-
atitis C journey. In this exciting era where the possibility of eliminating hepatitis C as a 
public health threat is becoming ever more realistic, it is crucial that the voices of the  
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